5.26 USD
▼-0.08-1.50%
盘后 5.38 0.00%
2026-09-15
市值
$1.30B
市盈率
—
EPS
-0.58
股息率
—
52 周区间
3.34 – 7.01
成交量
1.30M
Beta
0.25
目标价
10.94
52W 低 3.3452W 高 7.01
价格走势
公司简介
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.